Monopar Therapeutics' (MNPR) "Buy" Rating Reiterated at HC Wainwright

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright's price target suggests a potential upside of 33.33% from the company's current price. HC Wainwright also issued estimates for Monopar Therapeutics' Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.89) EPS, FY2026 earnings at ($1.68) EPS, FY2027 earnings at $0.72 EPS, FY2028 earnings at $2.08 EPS and FY2029 earnings at $3.35 EPS.

Separately, Piper Sandler reiterated an "overweight" rating and set a $76.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $44.00.

Monopar Therapeutics Price Performance

NASDAQ:MNPR traded down $4.59 during trading hours on Tuesday, reaching $30.00. 42,416 shares of the stock were exchanged, compared to its average volume of 358,675. The firm has a 50 day moving average of $38.29 and a 200 day moving average of $24.88. The stock has a market cap of $183.39 million, a PE ratio of -15.23 and a beta of 1.01. Monopar Therapeutics has a twelve month low of $1.72 and a twelve month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.87). Equities research analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of Monopar Therapeutics stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the transaction, the insider now directly owns 822,255 shares of the company's stock, valued at $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 34.90% of the company's stock.

Institutional Trading of Monopar Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. acquired a new position in Monopar Therapeutics in the 4th quarter valued at about $3,694,000. Janus Henderson Group PLC acquired a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $23,435,000. RA Capital Management L.P. bought a new position in shares of Monopar Therapeutics during the fourth quarter worth approximately $11,247,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Monopar Therapeutics during the fourth quarter worth approximately $13,182,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Monopar Therapeutics during the 4th quarter worth approximately $2,861,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.